Here are the 424B prospectus supplements from Vir Biotechnology, Inc. (VIR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIR filings page.
Vir Biotechnology, Inc. is offering 17,647,059 shares of common stock at a public offering price of $8.50 per share, with an underwriter option to purchase up to 2,647,058 additional shares for 30 days.
The offering is expected to provide net proceeds of approximately $141.1 million (or $162.3 million if the underwriters exercise their option in full), which Vir says it will use to fund its share of global clinical development and potential commercial launch costs for VIR-5500, other TCE programs using the PRO-XTEN® platform, and for working capital and general corporate purposes.
Vir Biotechnology is offering $200,000,000 of its common stock in a primary offering pursuant to a preliminary prospectus supplement dated February 24, 2026. The prospectus supplement states the offering is subject to completion and includes an underwriter option to purchase up to $30,000,000 of additional shares.
The filing discloses a recently executed Collaboration and License Agreement and Stock Purchase Agreement with Astellas dated February 19, 2026, under which Vir would receive $335 million in upfront and near-term consideration (including a $240 million cash upfront payment and a $75 million equity investment), and may receive up to $1.37 billion in future milestones, with global development costs for VIR-5500 shared 40% by Vir and 60% by Astellas. Shares outstanding were 139,474,954 as of December 31, 2025.